Akkermansia muciniphila
Also known as: A. muciniphila, Akkermansia
A recent 12-week randomized, double-blind, placebo-controlled trial in people with overweight/obese type 2 diabetes found no overall between-group benefit for weight or HbA1c; however, participants with low baseline A. muciniphila who received supplementation showed successful colonisation and significant reductions in body weight, fat mass and HbA1c. A systematic review (to March 2020) of 15 studies including animal and human work concluded that A. muciniphila supplementation shows promise for managing obesity and related metabolic complications but highlighted the need for further clinical trials.
Last reviewed: 2026-10-14 · 2 indexed studies
Set your location for accurate regulatory status
Saved on this device — no sign-in needed.
Overview
Akkermansia muciniphila is a gut bacterium proposed as a probiotic for modulating the microbiome in people with overweight, obesity and metabolic disease. Human clinical evidence is limited and suggests effects may depend on the recipient's baseline levels of the organism in the gut.
Mechanism & Function
Mechanism of Action
Clinical abstracts attribute effects to modulation of the gut microbiota via colonisation by A. muciniphila; clinical benefit in the RCT tracked with successful colonisation in participants who had low baseline levels.
Physiological Role
Resident gut bacterium implicated in gut ecosystem dynamics and host metabolic interactions; clinical evidence links colonisation level with metabolic outcomes in people with overweight/obesity and type 2 diabetes.
Primary Pathways
Performance / Health Relevance
Not primarily used for athletic performance. Evidence pertains to metabolic health outcomes (weight, fat mass, HbA1c) rather than exercise performance.
Evidence Review
Practical Use & Dosage
- Minimum Effective Dose
- Not established (no dose reported in provided abstracts)
- Optimal Range
- Not established
- Upper / Caution Level
- Not established
- Timing
- Not established
- Best Format
- Oral probiotic formulation (strain-specific product; e.g. AKK-WST01 in the RCT)
- Bioavailability
- Clinical benefit in the RCT was contingent on successful gut colonisation; colonisation efficiency varied with baseline A. muciniphila levels.
- Absorption Considerations
- Effectiveness appears to depend on ability to colonise the host gut microbiota; baseline abundance predicts colonisation success and clinical response.
Safety & Interactions
Side Effects
- •Limited safety data in available human abstracts; no major adverse events reported in the provided RCT abstract
Contraindications
- Immunocompromised states: caution with live microbial products (general probiotic consideration)
Drug Interactions
- •No specific interactions reported in the provided abstracts
Who Should Avoid
- •People with severe immunodeficiency or those advised to avoid live microbial products without medical supervision
Monitoring
Monitor clinical endpoints relevant to metabolic disease (weight, HbA1c) and consider baseline gut A. muciniphila levels if available, as colonisation and benefit may depend on baseline abundance.
Frequently Asked Questions
Auto-generated from indexed evidence — dosage, safety, interactions, and more.
When is Akkermansia muciniphila typically used or indicated?
Akkermansia muciniphila is most commonly used for: Support metabolic health in overweight/obesity, Adjunct for type 2 diabetes management, Modulation of gut microbiota composition. Resident gut bacterium implicated in gut ecosystem dynamics and host metabolic interactions; clinical evidence links colonisation level with metabolic outcomes in people with overweight/obesity and type 2 diabetes.
How does Akkermansia muciniphila work?
Clinical abstracts attribute effects to modulation of the gut microbiota via colonisation by A. muciniphila; clinical benefit in the RCT tracked with successful colonisation in participants who had low baseline levels.
What is the recommended dose of Akkermansia muciniphila?
The optimal range is Not established. with a minimum effective dose of Not established (no dose reported in provided abstracts). Best taken: Not established. Upper / caution level: Not established.
What are the side effects of Akkermansia muciniphila?
Reported side effects include: Limited safety data in available human abstracts; no major adverse events reported in the provided RCT abstract. Monitoring: Monitor clinical endpoints relevant to metabolic disease (weight, HbA1c) and consider baseline gut A. muciniphila levels if available, as colonisation and benefit may depend on baseline abundance.
Does Akkermansia muciniphila interact with medications?
Known or theoretical interactions: No specific interactions reported in the provided abstracts. Always check with a clinician before combining with prescription medication.
Who should avoid Akkermansia muciniphila?
Akkermansia muciniphila is generally not recommended for: People with severe immunodeficiency or those advised to avoid live microbial products without medical supervision; and Immunocompromised states: caution with live microbial products (general probiotic consideration).
How strong is the evidence for Akkermansia muciniphila?
Evidence level: Limited (overall score 43/100), based on 2 indexed studies on SuppIndex.
Research & References (2)
Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut.
12-week randomized, double-blind, placebo-controlled trial in 58 adults with overweight/obese type 2 diabetes comparing oral A. muciniphila (AKK-WST01) to placebo alongside lifestyle guidance.
A comprehensive systematic review of the effectiveness of Akkermansia muciniphila, a member of the gut microbiome, for the management of obesity and associated metabolic disorders.
Systematic review (search to March 2020) of 15 studies including human and animal models evaluating A. muciniphila supplementation for obesity and related metabolic disorders.
Related Ingredients
Other top-rated ingredients in General Health Ingredients.
Piperine
82/100A piperidine alkaloid (C₁₇H₁₉NO₃) that inhibits cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2E1), P-glycoprotein efflux transporters, and UDP-glucuronosyltransferases while enhancing intestinal permeability, digestive enzyme secretion, and splanchnic blood flow — collectively producing dramatic improvements in nutrient bioavailability.
CoQ10
78/100Endogenous lipid-soluble ubiquinone/ubiquinol that shuttles electrons in the mitochondrial respiratory chain and acts as a membrane antioxidant.
Beta-Glucan (Oat)
77/100Multiple randomized trials and meta-analyses report that ≥3 g/day oat beta-glucan lowers LDL and total cholesterol modestly. Acute feeding trials pooled in meta-analysis show dose- and molecular-weight–dependent reductions in postprandial glucose and insulin responses.
Research Overview
Limited EvidenceCite this ingredient
One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.
Stable URL
https://thesuppindex.com/ingredients/akkermansia-muciniphila
SuppIndex. (2026). Akkermansia muciniphila: Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/akkermansia-muciniphila
Based on 2 indexed studies · Evidence level: Limited.
Goal Ratings
Stack Compatibility
May be combined with prebiotics or other probiotics to support colonisation; evidence for specific combinations not reported in the provided abstracts.